{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:57:10Z","timestamp":1779310630314,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI111205"],"award-info":[{"award-number":["R01AI111205"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Superantigens (SAgs) play a major role in the pathogenesis of <jats:italic>Staphylococcus aureus<\/jats:italic> and are associated with several diseases, including food poisoning, bacterial arthritis, and toxic shock syndrome. Monoclonal antibodies to these SAgs, primarily TSST-1, SEB and SEA have been shown to provide protection in animal studies and to reduce clinical severity in bacteremic patients. Here we quantify the pre-existing antibodies against SAgs in many human plasma and IVIG samples and demonstrate that in a major portion of the population these antibody titers are suboptimal and IVIG therapy only incrementally elevates the anti-SAg titers. Our <jats:italic>in vitro<\/jats:italic> neutralization studies show that a combination of antibodies against SEA, SEB,and TSST-1 can provide broad neutralization of staphylococcal SAgs. We report a single fusion protein (TBA<jats:sub>225<\/jats:sub>) consisting of the toxoid versions of TSST-1, SEB and SEA and demonstrate its immunogenicity and protective efficacy in a mouse model of toxic shock. Antibodies raised against this fusion vaccine provide broad neutralization of purified SAgs and culture supernatants of multiple clinically relevant <jats:italic>S<\/jats:italic>. <jats:italic>aureus<\/jats:italic> strains. Our data strongly supports the use of this fusion protein as a component of an anti-virulence based multivalent toxoid vaccine against <jats:italic>S<\/jats:italic>. <jats:italic>aureus<\/jats:italic> disease.<\/jats:p>","DOI":"10.1038\/s41598-019-39890-z","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T11:06:43Z","timestamp":1551438403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["TBA225, a fusion toxoid vaccine for protection and broad neutralization of staphylococcal superantigens"],"prefix":"10.1038","volume":"9","author":[{"given":"Arundhathi","family":"Venkatasubramaniam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan P.","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant C.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Conley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Abaandou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Kailasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikuni","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier M.","family":"Djagbare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick W.","family":"Holtsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatice","family":"Karauzum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-4707","authenticated-orcid":false,"given":"M. Javad","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"issue":"Suppl 5","key":"39890_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/1469-0691.12570","volume":"20","author":"VG Fowler Jr.","year":"2014","unstructured":"Fowler, V. G. Jr. & Proctor, R. A. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect 20(Suppl 5), 66\u201375 (2014).","journal-title":"Clin Microbiol Infect"},{"key":"39890_CR2","doi-asserted-by":"crossref","unstructured":"Oliveira, D., Borges, A. & Simoes, M. Staphylococcus aureus Toxins and Their Molecular Activity in Infectious Diseases. Toxins (Basel) 10 (2018).","DOI":"10.3390\/toxins10060252"},{"issue":"Suppl 1","key":"39890_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S0924-8579(09)70544-8","volume":"34","author":"M Bassetti","year":"2009","unstructured":"Bassetti, M., Nicco, E. & Mikulska, M. Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int J Antimicrob Agents 34(Suppl 1), S15\u201319 (2009).","journal-title":"Int J Antimicrob Agents"},{"key":"39890_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1055\/s-2005-925528","volume":"26","author":"SF Bradley","year":"2005","unstructured":"Bradley, S. F. Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 26, 643\u2013649 (2005).","journal-title":"Semin Respir Crit Care Med"},{"key":"39890_CR5","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.4161\/hv.25182","volume":"9","author":"GB Pier","year":"2013","unstructured":"Pier, G. B. Will there ever be a universal Staphylococcus aureus vaccine? Hum Vaccin Immunother 9, 1865\u20131876 (2013).","journal-title":"Hum Vaccin Immunother"},{"key":"39890_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2013.3010","volume":"309","author":"VG Fowler","year":"2013","unstructured":"Fowler, V. G. et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309, 1368\u20131378 (2013).","journal-title":"JAMA"},{"key":"39890_CR7","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.4161\/hv.34407","volume":"10","author":"TB McNeely","year":"2014","unstructured":"McNeely, T. B. et al. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum Vaccin Immunother 10, 3513\u20133516 (2014).","journal-title":"Hum Vaccin Immunother"},{"key":"39890_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.22203\/eCM.v030a22","volume":"30","author":"RA Proctor","year":"2015","unstructured":"Proctor, R. A. Recent developments for Staphylococcus aureus vaccines: clinical and basic science challenges. Eur Cell Mater 30, 315\u2013326 (2015).","journal-title":"Eur Cell Mater"},{"key":"39890_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/infdis\/167.5.997","volume":"167","author":"PM Schlievert","year":"1993","unstructured":"Schlievert, P. M. Role of Superantigens in Human Disease. The Journal of Infectious Diseases 167, 997\u20131002 (1993).","journal-title":"The Journal of Infectious Diseases"},{"key":"39890_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/10408419009105728","volume":"17","author":"GA Bohach","year":"1990","unstructured":"Bohach, G. A., Fast, D. J., Nelson, R. D. & Schlievert, P. M. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17, 251\u2013272 (1990).","journal-title":"Crit Rev Microbiol"},{"key":"39890_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0198-8859(95)00145-X","volume":"45","author":"U Mahlknecht","year":"1996","unstructured":"Mahlknecht, U., Herter, M., Hoffmann, M. K., Niethammer, D. & Dannecker, G. E. The toxic shock syndrome toxin-1 induces anergy in human T cells in vivo. Hum Immunol 45, 42\u201345 (1996).","journal-title":"Hum Immunol"},{"key":"39890_CR12","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1073\/pnas.93.11.5425","volume":"93","author":"MF Hofer","year":"1996","unstructured":"Hofer, M. F. et al. Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis. Proc Natl Acad Sci USA 93, 5425\u20135430 (1996).","journal-title":"Proc Natl Acad Sci USA"},{"key":"39890_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4049\/jimmunol.1602109","volume":"200","author":"J Lee","year":"2018","unstructured":"Lee, J. et al. Induction of Immunosuppressive CD8(+)CD25(+)FOXP3(+) Regulatory T Cells by Suboptimal Stimulation with Staphylococcal Enterotoxin C1. J Immunol 200, 669\u2013680 (2018).","journal-title":"J Immunol"},{"key":"39890_CR14","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.4049\/jimmunol.0803953","volume":"183","author":"Y Tanriver","year":"2009","unstructured":"Tanriver, Y., Martin-Fontecha, A., Ratnasothy, K., Lombardi, G. & Lechler, R. Superantigen-activated regulatory T cells inhibit the migration of innate immune cells and the differentiation of naive T cells. J Immunol 183, 2946\u20132956 (2009).","journal-title":"J Immunol"},{"key":"39890_CR15","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.4049\/jimmunol.1400980","volume":"193","author":"AY Tilahun","year":"2014","unstructured":"Tilahun, A. Y., Chowdhary, V. R., David, C. S. & Rajagopalan, G. Systemic inflammatory response elicited by superantigen destabilizes T regulatory cells, rendering them ineffective during toxic shock syndrome. J Immunol 193, 2919\u20132930 (2014).","journal-title":"J Immunol"},{"key":"39890_CR16","doi-asserted-by":"crossref","unstructured":"Broker, B. M., Mrochen, D. & Peton, V. The T Cell Response to Staphylococcus aureus. Pathogens 5 (2016).","DOI":"10.3390\/pathogens5010031"},{"key":"39890_CR17","unstructured":"Maeurer, M., Zitvogel, L., Elder, E., Storkus, W. J. & Lotze, M. T. Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 14, 188\u2013197 (1995)."},{"key":"39890_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1074-7613(01)00113-3","volume":"14","author":"CT Morita","year":"2001","unstructured":"Morita, C. T. et al. Superantigen recognition by gammadelta T cells: SEA recognition site for human Vgamma2 T cell receptors. Immunity 14, 331\u2013344 (2001).","journal-title":"Immunity"},{"key":"39890_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/icb.2011.90","volume":"90","author":"JL Hayworth","year":"2012","unstructured":"Hayworth, J. L. et al. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens. Immunol Cell Biol 90, 699\u2013709 (2012).","journal-title":"Immunol Cell Biol"},{"key":"39890_CR20","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1128\/IAI.00177-11","volume":"79","author":"SA Rieder","year":"2011","unstructured":"Rieder, S. A., Nagarkatti, P. & Nagarkatti, M. CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II\/T cell receptor interaction results in acute lung injury. Infect Immun 79, 3141\u20133148 (2011).","journal-title":"Infect Immun"},{"key":"39890_CR21","first-page":"824","volume":"215","author":"PA Szabo","year":"2017","unstructured":"Szabo, P. A. et al. Invariant Natural Killer T Cells Are Pathogenic in the HLA-DR4-Transgenic Humanized Mouse Model of Toxic Shock Syndrome and Can Be Targeted to Reduce Morbidity. J Infect Dis 215, 824\u2013829 (2017).","journal-title":"J Infect Dis"},{"key":"39890_CR22","doi-asserted-by":"crossref","unstructured":"Shaler, C. R. et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol 15, e2001930 (2017).","DOI":"10.1371\/journal.pbio.2001930"},{"key":"39890_CR23","doi-asserted-by":"crossref","unstructured":"Salgado-Pabon, W. et al. Superantigens are critical for Staphylococcus aureus Infective endocarditis, sepsis, and acute kidney injury. MBio 4 (2013).","DOI":"10.1128\/mBio.00494-13"},{"key":"39890_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1128\/CMR.00104-12","volume":"26","author":"AR Spaulding","year":"2013","unstructured":"Spaulding, A. R. et al. Staphylococcal and Streptococcal Superantigen Exotoxins. Clinical Microbiology Reviews 26, 422\u2013447 (2013).","journal-title":"Clinical Microbiology Reviews"},{"key":"39890_CR25","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1016\/j.vaccine.2012.05.067","volume":"30","author":"AR Spaulding","year":"2012","unstructured":"Spaulding, A. R. et al. Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine 30, 5099\u20135109 (2012).","journal-title":"Vaccine"},{"key":"39890_CR26","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1128\/IAI.72.7.4061-4071.2004","volume":"72","author":"S Holtfreter","year":"2004","unstructured":"Holtfreter, S. et al. egc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. Infect Immun 72, 4061\u20134071 (2004).","journal-title":"Infect Immun"},{"key":"39890_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0966-842X(00)01793-5","volume":"8","author":"AC Papageorgiou","year":"2000","unstructured":"Papageorgiou, A. C. & Acharya, K. R. Microbial superantigens: from structure to function. Trends Microbiol 8, 369\u2013375 (2000).","journal-title":"Trends Microbiol"},{"key":"39890_CR28","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1086\/314977","volume":"180","author":"S Bavari","year":"1999","unstructured":"Bavari, S., Ulrich, R. G. & LeClaire, R. D. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens. J Infect Dis 180, 1365\u20131369 (1999).","journal-title":"J Infect Dis"},{"key":"39890_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/infdis\/jis462","volume":"206","author":"RP Adhikari","year":"2012","unstructured":"Adhikari, R. P. et al. Lower Antibody Levels to Staphylococcus aureus Exotoxins Are Associated With Sepsis in Hospitalized Adults With Invasive S. aureus Infections. J Infect Dis 206, 915\u2013923 (2012).","journal-title":"J Infect Dis"},{"key":"39890_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-014-0447-4","volume":"16","author":"S Donovan","year":"2014","unstructured":"Donovan, S. & Bearman, G. M. Use of intravenous immunoglobulin in critically ill patients. Curr Infect Dis Rep 16, 447 (2014).","journal-title":"Curr Infect Dis Rep"},{"key":"39890_CR31","first-page":"877","volume":"64","author":"SS Kadri","year":"2017","unstructured":"Kadri, S. S. et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis 64, 877\u2013885 (2017).","journal-title":"Clin Infect Dis"},{"key":"39890_CR32","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1067\/mai.2001.117820","volume":"108","author":"PM Schlievert","year":"2001","unstructured":"Schlievert, P. M. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 108, S107\u2013110 (2001).","journal-title":"J Allergy Clin Immunol"},{"key":"39890_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2146\/ajhp140359","volume":"72","author":"PJ Shah","year":"2015","unstructured":"Shah, P. J., Vakil, N. & Kabakov, A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Health Syst Pharm 72, 1013\u20131019 (2015).","journal-title":"Am J Health Syst Pharm"},{"key":"39890_CR34","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/nprot.2007.321","volume":"2","author":"FH Niesen","year":"2007","unstructured":"Niesen, F. H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2, 2212\u20132221 (2007).","journal-title":"Nat Protoc"},{"key":"39890_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00320315","volume":"43","author":"F Berthold","year":"1981","unstructured":"Berthold, F. Isolation of human monocytes by Ficoll density gradient centrifugation. Blut 43, 367\u2013371 (1981).","journal-title":"Blut"},{"key":"39890_CR36","doi-asserted-by":"publisher","first-page":"e65384","DOI":"10.1371\/journal.pone.0065384","volume":"8","author":"H Karauzum","year":"2013","unstructured":"Karauzum, H. et al. Structurally Designed Attenuated Subunit Vaccines for S. aureus LukS-PV and LukF-PV Confer Protection in a Mouse Bacteremia Model. PLoS One 8, e65384 (2013).","journal-title":"PLoS One"},{"key":"39890_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/INF.0b013e31818cb0c4","volume":"28","author":"AE Chen","year":"2009","unstructured":"Chen, A. E. et al. Discordance between Staphylococcus aureus nasal colonization and skin infections in children. Pediatr Infect Dis J 28, 244\u2013246 (2009).","journal-title":"Pediatr Infect Dis J"},{"key":"39890_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1172\/JCI116240","volume":"91","author":"S Takei","year":"1993","unstructured":"Takei, S., Arora, Y. K. & Walker, S. M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest 91, 602\u2013607 (1993).","journal-title":"J Clin Invest"},{"key":"39890_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1365-2141.1995.tb08404.x","volume":"89","author":"M Toungouz","year":"1995","unstructured":"Toungouz, M., Denys, C. H., De Groote, D. & Dupont, E. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 89, 698\u2013703 (1995).","journal-title":"Br J Haematol"},{"key":"39890_CR40","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s10156-007-0551-6","volume":"13","author":"C Yanagisawa","year":"2007","unstructured":"Yanagisawa, C., Hanaki, H., Natae, T. & Sunakawa, K. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother 13, 368\u2013372 (2007).","journal-title":"J Infect Chemother"},{"key":"39890_CR41","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1128\/JCM.43.9.4628-4634.2005","volume":"43","author":"J Parsonnet","year":"2005","unstructured":"Parsonnet, J. et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 43, 4628\u20134634 (2005).","journal-title":"J Clin Microbiol"},{"key":"39890_CR42","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1128\/iai.61.12.5333-5338.1993","volume":"61","author":"BG Stiles","year":"1993","unstructured":"Stiles, B. G., Bavari, S., Krakauer, T. & Ulrich, R. G. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect Immun 61, 5333\u20135338 (1993).","journal-title":"Infect Immun"},{"key":"39890_CR43","doi-asserted-by":"publisher","first-page":"4S","DOI":"10.1007\/BF01540887","volume":"15","author":"PM Schlievert","year":"1995","unstructured":"Schlievert, P. M. et al. Molecular structure of staphylococcus and streptococcus superantigens. J Clin Immunol 15, 4S\u201310S (1995).","journal-title":"J Clin Immunol"},{"key":"39890_CR44","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1086\/314977","volume":"180","author":"S Bavari","year":"1999","unstructured":"Bavari, S., Ulrich, R. G. & LeClaire, R. D. Cross-Reactive Antibodies Prevent the Lethal Effects of Staphylococcus auveus Superantigens. The Journal of Infectious Diseases 180, 1365\u20131369 (1999).","journal-title":"The Journal of Infectious Diseases"},{"key":"39890_CR45","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0264-410X(98)00176-5","volume":"16","author":"RG Ulrich","year":"1998","unstructured":"Ulrich, R. G., Olson, M. A. & Bavari, S. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 16, 1857\u20131864 (1998).","journal-title":"Vaccine"},{"key":"39890_CR46","unstructured":"Ulrich, R. G., Olson, M. A. & Bavari, S. Bacterial superantigen vaccines (2004)."},{"key":"39890_CR47","unstructured":"Ulrich, R. G., Olson, M. A. & Bavari, S. Bacterial superantigen vaccines (2002)."},{"key":"39890_CR48","unstructured":"Ulrich, R. G. Fusion protein of streptococcal pyrogenic exotoxins (2006)."},{"key":"39890_CR49","unstructured":"Ulrich, R. G. Altered superantigen toxins (2010)."},{"key":"39890_CR50","unstructured":"Aman, M. J., Adhikari, R. P., Shulenin, S., Holtsberg, F. W. & Karauzum, H. Toxoid Peptides Derived from Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions Thereof (2016)."},{"key":"39890_CR51","unstructured":"Ulrich, R. G., Olson, M. A. & Bavari, S. Bacterial superantigen vaccines (2011)."},{"key":"39890_CR52","doi-asserted-by":"crossref","unstructured":"Chen, W. H. et al. The safety and immunogenicity of a parenterally administered structure-based rationally modified recombinant Staphylococcal enterotoxin B protein vaccine, STEBVax. Clinical and Vaccine Immunology (2016).","DOI":"10.1128\/CVI.00399-16"},{"key":"39890_CR53","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.182.3.711","volume":"182","author":"KR Hudson","year":"1995","unstructured":"Hudson, K. R. et al. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. The Journal of Experimental Medicine 182, 711\u2013720 (1995).","journal-title":"The Journal of Experimental Medicine"},{"key":"39890_CR54","doi-asserted-by":"crossref","unstructured":"Kozono, H., Parker, D., White, J., Marrack, P. & Kappler, J. Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. Immunity 3, 187\u2013196 (1995).","DOI":"10.1016\/1074-7613(95)90088-8"},{"key":"39890_CR55","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1128\/CVI.00399-16","volume":"23","author":"WH Chen","year":"2016","unstructured":"Chen, W. H. et al. Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. Clin Vaccine Immunol 23, 918\u2013925 (2016).","journal-title":"Clin Vaccine Immunol"},{"key":"39890_CR56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijid.2003.12.005","volume":"8","author":"K Azuma","year":"2004","unstructured":"Azuma, K. et al. Detection of circulating superantigens in an intensive care unit population. Int J Infect Dis 8, 292\u2013298 (2004).","journal-title":"Int J Infect Dis"},{"key":"39890_CR57","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1097\/INF.0000000000000967","volume":"35","author":"DS Kim","year":"2016","unstructured":"Kim, D. S. et al. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea. Pediatr Infect Dis J 35, e60\u201364 (2016).","journal-title":"Pediatr Infect Dis J"},{"key":"39890_CR58","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.4161\/hv.24844","volume":"9","author":"Y Poovorawan","year":"2013","unstructured":"Poovorawan, Y. et al. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother 9, 1679\u20131684 (2013).","journal-title":"Hum Vaccin Immunother"},{"key":"39890_CR59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","volume":"23","author":"M Rennels","year":"2004","unstructured":"Rennels, M. et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 23, 429\u2013435 (2004).","journal-title":"Pediatr Infect Dis J"},{"key":"39890_CR60","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1473-3099(16)30115-3","volume":"16","author":"M Schwameis","year":"2016","unstructured":"Schwameis, M. et al. Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. Lancet Infect Dis 16, 1036\u20131044 (2016).","journal-title":"Lancet Infect Dis"},{"key":"39890_CR61","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/infdis\/jix096","volume":"215","author":"H Karauzum","year":"2017","unstructured":"Karauzum, H. et al. Lethal CD4 T Cell Responses Induced by Vaccination Against Staphylococcus aureus Bacteremia. J Infect Dis 215, 1231\u20131239 (2017).","journal-title":"J Infect Dis"},{"key":"39890_CR62","unstructured":"Spaulding, A. R. et al. Vaccination Against Staphylococcus aureus Pneumonia. J Infect Dis (2014)."},{"key":"39890_CR63","doi-asserted-by":"crossref","unstructured":"Fritz, S. A. et al. A Serologic Correlate of Protective Immunity Against Community-Onset Staphylococcus aureus Infection. Clin Infect Dis (2013).","DOI":"10.1093\/cid\/cit123"},{"key":"39890_CR64","doi-asserted-by":"publisher","first-page":"e38567","DOI":"10.1371\/journal.pone.0038567","volume":"7","author":"RP Adhikari","year":"2012","unstructured":"Adhikari, R. P. et al. Novel Structurally Designed Vaccine for S. aureus alpha-Hemolysin: Protection against Bacteremia and Pneumonia. PLoS One 7, e38567 (2012).","journal-title":"PLoS One"},{"key":"39890_CR65","doi-asserted-by":"publisher","first-page":"e0137874","DOI":"10.1371\/journal.pone.0137874","volume":"10","author":"RP Adhikari","year":"2015","unstructured":"Adhikari, R. P. et al. Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs. PLoS One 10, e0137874 (2015).","journal-title":"PLoS One"},{"key":"39890_CR66","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1016\/j.vaccine.2016.09.061","volume":"34","author":"RP Adhikari","year":"2016","unstructured":"Adhikari, R. P., Thompson, C. D., Aman, M. J. & Lee, J. C. Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections. Vaccine 34, 6402\u20136407 (2016).","journal-title":"Vaccine"},{"key":"39890_CR67","doi-asserted-by":"crossref","unstructured":"Varshney, A. K. et al. Staphylococcal Enterotoxin B-Specific Monoclonal Antibody 20B1 Successfully Treats Diverse Staphylococcus aureus Infections. J Infect Dis (2013).","DOI":"10.1093\/infdis\/jit421"},{"key":"39890_CR68","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1128\/iai.65.10.4216-4221.1997","volume":"65","author":"IM Nilsson","year":"1997","unstructured":"Nilsson, I. M., Lee, J. C., Bremell, T., Ryden, C. & Tarkowski, A. The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun 65, 4216\u20134221 (1997).","journal-title":"Infect Immun"},{"key":"39890_CR69","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1086\/377308","volume":"188","author":"DL Hu","year":"2003","unstructured":"Hu, D. L. et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis 188, 743\u2013752 (2003).","journal-title":"J Infect Dis"},{"key":"39890_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/protein\/gzs094","volume":"26","author":"DM Mattis","year":"2013","unstructured":"Mattis, D. M. et al. Engineering a soluble high-affinity receptor domain that neutralizes staphylococcal enterotoxin C in rabbit models of disease. Protein Eng Des Sel 26, 133\u2013142 (2013).","journal-title":"Protein Eng Des Sel"},{"key":"39890_CR71","doi-asserted-by":"crossref","unstructured":"Aguilar, J. L. et al. Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence, 0 (2016).","DOI":"10.1080\/21505594.2016.1231295"},{"key":"39890_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1099\/00222615-28-3-163","volume":"28","author":"H Humphreys","year":"1989","unstructured":"Humphreys, H. et al. Enterotoxin production by Staphylococcus aureus isolates from cases of septicaemia and from healthy carriers. J Med Microbiol 28, 163\u2013172 (1989).","journal-title":"J Med Microbiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39890-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:59:47Z","timestamp":1671260387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39890-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["39890"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-39890-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"2 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.A. has stocks in integrated Biotherapeutics, H.K. and F.W.H. have stock options in integrated Biotherapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3279"}}